A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Alferminogene-tadenovec (Primary)
  • Indications Angina pectoris; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms AFFIRM
  • Sponsors Angionetics
  • Most Recent Events

    • 20 Mar 2017 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
    • 20 Mar 2017 Planned primary completion date changed from 1 May 2019 to 1 Sep 2019.
    • 20 Mar 2017 Planned initiation date changed from 1 Apr 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top